Biovitrum AB has acquired Swedish Orphan International AB and the combined businesses have become a force to reckon with in Europe in niche specialty and orphan drugs. The deal is valued at SEK3.5 B (US$493.2 M) and the newly formed company, Swedish Orphan Biovitrum, is aiming for sales of SEK5 B (US$704.2 M) by 2015.